Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib and Trastuzumab in HER2+ Breast Cancer
NCT03847818Phase 2Unknown
- Sponsor
- Shandong University
- Start
- Mar 2019
- Primary completion
- Mar 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Shandong University. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03847818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03847818.